174 related articles for article (PubMed ID: 33850301)
21. The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.
Onabajo OO; Muchmore B; Prokunina-Olsson L
J Interferon Cytokine Res; 2019 Oct; 39(10):636-641. PubMed ID: 31241411
[TBL] [Abstract][Full Text] [Related]
22. Polymorphism rs368234815 of interferon-λ4 gene and generation of antibodies to hepatitis B virus surface antigen in extracorporeal dialysis patients.
Grzegorzewska AE; Świderska MK; Marcinkowski W; Mostowska A; Jagodziński PP
Expert Rev Vaccines; 2020 Mar; 19(3):293-303. PubMed ID: 32228249
[No Abstract] [Full Text] [Related]
23. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?
O'Brien TR; Jackson SS
J Interferon Cytokine Res; 2019 Oct; 39(10):618-626. PubMed ID: 31161939
[TBL] [Abstract][Full Text] [Related]
24. Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus.
Waldenström J; Hellstrand K; Westin J; Nilsson S; Christensen P; Färkkilä M; Mørch K; Langeland N; Norkrans G; Lagging M
Scand J Gastroenterol; 2021 Jul; 56(7):849-854. PubMed ID: 34078234
[TBL] [Abstract][Full Text] [Related]
25. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
[TBL] [Abstract][Full Text] [Related]
26. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
27. IFNL4: Notable variants and associated phenotypes
Fang MZ; Jackson SS; O'Brien TR
Gene; 2020 Mar; 730():144289. PubMed ID: 31846709
[TBL] [Abstract][Full Text] [Related]
28.
Rugwizangoga B; Andersson ME; Kabayiza JC; Nilsson MS; Ármannsdóttir B; Aurelius J; Nilsson S; Hellstrand K; Lindh M; Martner A
Front Cell Infect Microbiol; 2019; 9():340. PubMed ID: 31637221
[TBL] [Abstract][Full Text] [Related]
29. Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes.
Lang Kuhs KA; Kuniholm MH; Pfeiffer RM; Chen S; Desai S; Edlin BR; Peters MG; Plankey M; Sharp GB; Strickler HD; Villacres MC; Quinn TC; Gange SJ; Prokunina-Olsson L; Greenblatt RM; O'Brien TR
PLoS One; 2015; 10(10):e0138827. PubMed ID: 26431156
[TBL] [Abstract][Full Text] [Related]
30. Its all about IFN-λ4: Protective role of IFNL4 polymorphism against COVID-19-related pneumonia in females.
Matic S; Milovanovic D; Mijailovic Z; Djurdjevic P; Sazdanovic P; Stefanovic S; Todorovic D; Popovic S; Vitosevic K; Vukicevic V; Vukic M; Vukovic N; Milivojevic N; Zivanovic M; Jakovljevic V; Filipovic N; Djordjevic N; Baskic D
J Med Virol; 2023 Oct; 95(10):e29152. PubMed ID: 37812032
[TBL] [Abstract][Full Text] [Related]
31. No Association of IFNL4 Genotype With Opportunistic Infections and Cancers Among Men With Human Immunodeficiency Virus 1 Infection.
Fang MZ; Jackson SS; Pfeiffer RM; Kim EY; Chen S; Hussain SK; Jacobson LP; Martinson J; Prokunina-Olsson L; Thio CL; Duggal P; Wolinsky S; O'Brien TR
Clin Infect Dis; 2023 Feb; 76(3):521-527. PubMed ID: 36573283
[TBL] [Abstract][Full Text] [Related]
32. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
[TBL] [Abstract][Full Text] [Related]
33. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
Grzegorzewska AE
Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
[TBL] [Abstract][Full Text] [Related]
34. Genetics of the Human Interferon Lambda Region.
Prokunina-Olsson L
J Interferon Cytokine Res; 2019 Oct; 39(10):599-608. PubMed ID: 31070498
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
Riva E; Scagnolari C; Turriziani O; Antonelli G
Clin Microbiol Infect; 2014 Dec; 20(12):1237-45. PubMed ID: 25273834
[TBL] [Abstract][Full Text] [Related]
36. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
[TBL] [Abstract][Full Text] [Related]
38. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
Sakr AA; Ahmed AE; Abd El-Maksoud MDE; Gamal A; El-Garem H; Ahmed OM
Infect Genet Evol; 2020 Dec; 86():104606. PubMed ID: 33127459
[TBL] [Abstract][Full Text] [Related]
39. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.
Rauff B; Amar A; Chudhary SA; Mahmood S; Tayyab GUN; Hanif R
Arch Virol; 2021 Apr; 166(4):1047-1056. PubMed ID: 33528661
[TBL] [Abstract][Full Text] [Related]
40. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.
Petta S; Valenti L; Tuttolomondo A; Dongiovanni P; Pipitone RM; Cammà C; Cabibi D; Di Marco V; Fracanzani AL; Badiali S; Nobili V; Fargion S; Grimaudo S; Craxì A
Hepatology; 2017 Dec; 66(6):1885-1893. PubMed ID: 28741298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
